Multiple sclerosis that is progressive from the time of onset -: Clinical characteristics and progression of disability

被引:61
作者
Andersson, PB
Waubant, E
Gee, L
Goodkin, DE
机构
[1] Univ Calif San Francisco, Sch Med, Mt Zion Multiple Sclerosis Ctr, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Sch Med, Dept Biostat & Epidemiol, San Francisco, CA 94115 USA
关键词
D O I
10.1001/archneur.56.9.1138
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To use the new consensus definitions of primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) to report the demographic, clinical, and natural history characteristics of multiple sclerosis (MS) that is progressive from the time of onset. Design: Retrospective study by database/chart review and telephone interview. Setting: Multiple sclerosis clinic at a university teaching hospital. Patients: Eighty-three patients (prevalence, 6.9%) with PPMS and 12 patients (prevalence, 1.0%) with PRMS were studied. Results: Fifty-nine percent of the patients with PPMS (n=49) and 67% of the patients with PRMS (n=8) were women. Mean +/-SD ages at the time of onset were 41.2 +/- 10.5 and 38.0 +/- 7.3 years, respectively; mean disease duration was 14.2 +/- 8.8 and 12.2 +/- 6.5 years, respectively. The initial symptoms involved leg weakness in 94% of the patients with PPMS (n = 78) and 100% of the patients with PRMS (n = 12). For the PPMS cohort, a syndrome consistent with isolated myelopathy was found in 36% of patients (n = 30) and arm weakness without leg weakness did not occur. Mean +/- SEM time of progression to a score of 6.0 on the Expanded Disability Status Scale was 10.2 +/- 1.0 years for patients with PPMS and 10.9 +/- 2.6 years for patients with PRMS. Conclusions: The clinical characteristics and disability progression of these MS subtypes were indistinguishable, with the exception of 1 or 2 relapses in patients with PRMS that occurred 8 months to 9 years after the onset of symptoms. We see little reason to consider PPMS and PRMS separate clinical entities; however, whether they can be better distinguished by radiological, histopathological, or immunological markers of disease activity remains unknown.
引用
收藏
页码:1138 / 1142
页数:5
相关论文
共 20 条
  • [1] BRAIN MRI CORRELATES OF COGNITIVE IMPAIRMENT IN PRIMARY AND SECONDARY PROGRESSIVE MULTIPLE-SCLEROSIS
    COMI, G
    FILIPPI, M
    MARTINELLI, V
    CAMPI, A
    RODEGHER, M
    ALBERONI, M
    SIRABIAN, G
    CANAL, N
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1995, 132 (02) : 222 - 227
  • [2] ACUTE-ONSET AND INSIDIOUS-ONSET MYELOPATHY OF UNDETERMINED ETIOLOGY - CONTRIBUTION OF PARACLINICAL TESTS TO THE DIAGNOSIS OF MULTIPLE-SCLEROSIS
    FILIPPI, M
    MARTINELLI, V
    LOCATELLI, T
    MEDAGLINI, S
    POGGI, A
    VISCIANI, A
    SCOTTI, G
    CANAL, N
    COMI, G
    [J]. JOURNAL OF NEUROLOGY, 1990, 237 (03) : 171 - 176
  • [3] Soluble E-selectin in multiple sclerosis: Raised concentrations in patients with primary progressive disease
    Giovannoni, G
    Thorpe, JW
    Kidd, D
    Kendall, BE
    Moseley, IF
    Thompson, AJ
    Keir, G
    Miller, DH
    Feldmann, M
    Thompson, EJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (01) : 20 - 26
  • [4] Goodkin D E, 1996, Mult Scler, V1, P393
  • [5] LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS
    GOODKIN, DE
    RUDICK, RA
    MEDENDORP, SV
    DAUGHTRY, MM
    SCHWETZ, KM
    FISCHER, J
    VANDYKE, C
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (01) : 30 - 40
  • [6] EXACERBATION RATES AND ADHERENCE TO DISEASE TYPE IN A PROSPECTIVELY FOLLOWED-UP POPULATION WITH MULTIPLE-SCLEROSIS - IMPLICATIONS FOR CLINICAL-TRIALS
    GOODKIN, DE
    HERTSGAARD, D
    RUDICK, RA
    [J]. ARCHIVES OF NEUROLOGY, 1989, 46 (10) : 1107 - 1112
  • [7] Goodkin DE, 1998, ANN NEUROL, V43, P530
  • [8] KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
  • [9] Defining the clinical course of multiple sclerosis: Results of an international survey
    Lublin, FD
    Reingold, SC
    [J]. NEUROLOGY, 1996, 46 (04) : 907 - 911
  • [10] Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK
    McDonnell, GV
    Hawkins, SA
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (04) : 451 - 454